NOVARTIS

TAF MEK melanoma - Home - HCP

Prescribing information

Image

Image

TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma

TAFINLAR in combination with MEKINIST is indicated in adult patients with unresectable or metastatic melanoma with a *BRAF* V600 mutation.[1,2]

TAFINLAR in combination with MEKINIST is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a *BRAF* V600 mutation, following complete resection.[1,2]

For the full safety profile, please refer to the Summary of Product Characteristics (SmPC) for TAFINLAR and MEKINIST.

Adverse event reporting: Details of how to report adverse events are available at the bottom of the page. Please refer to the respective SmPC for all licensed indications.

Please use the buttons below to find out more about melanoma diagnosis and staging, and TAFINLAR and MEKINIST mechanism of action, efficacy, safety profile and patient management.

BRAF V600, mutation of the *BRAF* gene at valine (V) 600; SmPC, summary of product characteristics.

References

1. TAFINLAR (dabrafenib) Summary of Product Characteristics.

2. MEKINIST (trametinib) Summary of Product Characteristics.

Diagnosis and staging

Diagnosis and staging

See more details

Hide details

Mechanism of action

Mechanism of action

See more details

Hide details

Efficacy

Efficacy

See more details

Hide details

Safety profile

Safety profile

See more details

Hide details

Management of patients with BRAF-positive melanoma

Management of patients with BRAF-positive melanoma

See more details

Hide details

UK | April 2025 | FA-11217996-1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.
